Extended Data Fig. 10: Comparisons of immune activation properties of ALPK1, STING, and TLR7/8 agonists.
From: Agonists for cytosolic bacterial receptor ALPK1 induce antitumour immunity
a, Induction of CXCL10, IL-6, and TNF by increasing doses of UDSP-Hep, the TLR7 agonist 41c-A from Roche, and ADU-S100 in human PBMCs (three donors). Shown are concentrations of the cytokines in the supernatants. b, Quantification (n = 3) of anti-CD86, CD80, and CD40 staining of purified iCD103-DCs treated with PBS, LPS, UDSP-Hep or ADU-S100. The histograms are shown in Fig. 5c. c, d, WT and Alpk1−/− BMDMs were treated with PBS, UDSP-Hep, R848, or ADU-S100. Shown are histograms (c) and quantification (d, n = 3) of anti-CD86 staining of the cells. e, f, OT-I CD8+ T cells were co-cultured for 72 h with WT and Alpk1−/− BMDMs pre-stimulated with OVA alone or in combination with an indicated immune agonist. Shown are flow cytometry histograms (e) and quantification (f, n = 3) of total T-cell numbers. g, Viability of anti-CD3ε/CD28-activated mouse CD3+ T cells after indicated treatments (n = 3). h, Growth curves of Hepa 1-6 tumours treated with PBS, UDSP-Hep (50 μg per mouse), or DMXAA (50 μg per mouse) (mean ± s.e.m., n = 8 for PBS and 9 for other two groups). Two-way ANOVA was used for statistical comparisons. a, b, d, f, g, mean ± s.d. All data are representative of three independent experiments.
